Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PHGE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsBiomX appoints Roy Rousso as Chief Business Officer with $143K annual fee and 200K shares
Filed May 28, 2026 · Period ending May 27, 2026 · ~1 min read
Key Changes
-
medium
Roy Rousso appointed Chief Business Officer effective July 1, 2026, bringing two decades of digital infrastructure and technology leadership experience from roles including Head of Global Business Development at Flexnode.
Item 5.02 verify on EDGAR → -
medium
Rousso to receive 200,000 shares vesting equally over three years, subject to Board approval of new equity incentive plan. Accelerated vesting applies if terminated without cause or upon change of control.
Item 5.02 verify on EDGAR → -
low
Compensation structured as consulting arrangement at 70% engagement: $11,900 monthly ($143K annually) plus potential 50% performance bonus based on Board-established milestones.
Item 5.02 verify on EDGAR → -
low
Agreement includes standard protections: 60-day termination notice, twelve-month non-compete and non-solicitation restrictions, and confidentiality obligations.
Item 5.02 verify on EDGAR →
Summary
BiomX has created a new Chief Business Officer position and hired Roy Rousso, a veteran technology executive, to fill it starting July 1, 2026. The move signals the company's intent to strengthen its commercial capabilities, though the part-time nature of the role (70% engagement) suggests a measured approach to expanding the leadership team.
Rousso's background in digital infrastructure and business development could help BiomX advance partnerships or commercialization efforts. The compensation package totals roughly $143,000 annually in cash fees plus 200,000 shares vesting over three years. The equity award requires Board approval of a new incentive plan, which hasn't been established yet—a detail investors should monitor.
For a small biotech, this represents meaningful potential dilution, though the three-year vesting schedule ties Rousso's interests to long-term value creation. Retail investors should watch for the formal establishment of the equity incentive plan and any subsequent disclosures about Rousso's specific objectives or milestones. The company's next quarterly report should provide context on how this hire fits into BiomX's broader strategic priorities and pipeline development plans.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Subject to approval by the Board and the terms of a Company equity incentive plan which the Company intend to establish, Mr. Rousso is entitled to an award under such plan of 200,000 shares of the Company’s common stock, vesting in three equal annual installments on the first, second and third anniversaries of July 1, 2026, subject to Mr. Rousso’s continued engagement.
Rousso is entitled to 200,000 shares of common stock vesting equally over three years, subject to Board approval and establishment of an equity incentive plan. The award includes accelerated vesting provisions upon termination without cause or change of control, where he would be credited with an additional six months of service. This equity grant represents potential dilution to existing shareholders.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The Company may terminate for cause immediately, or without cause upon not less than 60 days’ prior written notice (with the Company able to pay in lieu of notice). Mr. Rousso may terminate upon not less than 60 days’ prior written notice. ... It also includes confidentiality, non-competition (twelve months), and non-solicitation (twelve months) covenants.
The consulting agreement includes standard termination provisions with 60 days' notice required by either party (except for immediate cause termination). Rousso is subject to twelve-month non-competition and non-solicitation restrictions, along with confidentiality obligations, protecting the company's business interests post-engagement.
Event · Item 9.01 — Financial Statements and Exhibits
BiomX entered a consulting agreement with Roy Rousso on May 20, 2026.
Added in current filing · verify on EDGAR →
Consulting Agreement, dated May 20, 2026, between BiomX Inc. and Roy Rousso.
BiomX Inc. entered into a consulting agreement with Roy Rousso effective May 20, 2026.Without additional context about Mr. Rousso's role or the nature of services, the materiality and investor impact remain unclear.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 28, 2026 · How we verify